Slawomir A. Dutkiewicz

Learn More
This is a controlled efficacy study with doxazosin (4 mg/day) in the long-term management of 64 ambulatory patients with benign prostatic hyperplasia (BPH). Doxazosin was given for 72 weeks and is being continued. Twenty-three controls were treated with prazosin (Minipress-4 mg/day) for 24 weeks, after which the results were similar in both the doxazosin(More)
We comparatively evaluated urethral stricture (US) treatment outcomes, efficacy and complications, using either holmium laser endourethrotomy (HLU) or optical internal urethrotomy (OIU) since studies such as this are scarce in literature. During 2003–2008, 50 men aged 17–78 years were operated on for primary or refractory US, 32 (64%) and 18 (36%) patients,(More)
The aim of the prospective pilot study was evaluating efficacy and tolerance of pharma-cological more complete androgen blockade (mMAB) by using Zoladex LA 10.8 mg, Casodex 50 mg and Proscar 5 mg in patients with advanced prostate cancer (T3,Nx Mx-1). Methods: This five-year study involved 14 patients aged 67–82 years (average 73). Zoladex LA was(More)
This part of our study presents results of laboratory evaluations in patients with BPH during treatment with prazosin and doxazosin. After 72 weeks serum PSA and PAP fell by 40.2% and 82%, respectively. Blood urea nitrogen concentration decreased by 28.5% and serum creatinine by 20.8%. The results confirm long-term favourable effects of the therapy of(More)
A total of 89 patients with benign prostatic hyperplasia (BPH) were treated pharmacologically for 4 months: 51 received Cernilton and 38 Tadenan (controls). Significant subjective improvement was found in 78% of the patients in the Cernilton group compared to only 55% of the Tadenan-treated patients. The obstructive and irritative symptoms responded best to(More)
The relationship between plasma PSA, prostatic adenoma mass (AM), retention volume (RV) and age was studied in 112 men with benign prostatic hypertrophy (BPH). Their age ranged from 48 to 85 years. Mean PSA was 6.9 ng/ml (SD 6.6) and did not exceed 10 ng/ml in 81.2% of the patients. Mean AM and RV were 66.2 g (SD 36) and 51.7 ml (SD 1.3), respectively.(More)
Until recently metabolism and expression of thyroid hormones was considered not to occur in the tissues of the testes. Lately, specific receptors for triiodothyronine have been found in the nuclei of human testicular cells which shows that testicular tissue requires hormonal action [9]. The aim of the present study was to evaluate if the prohormone(More)